BNT3214-01: Testing different dose levels of a new drug (called BNT3214) in people with advanced or metastatic solid cancersA Phase I/IIa, First-in-human, Open-label, Multi-site, Multi-regional, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors

Exclusion

• Untreated or symptomatic central nervous system (CNS) metastases and leptomeningeal disease.
• Have a primary CNS malignancy.
• Have active, or a history of, pneumonitis requiring treatment with steroids, or have active, or a history of, interstitial lung disease.
• Have clinically significant pulmonary complications including, but not limited to, chronic obstructive pulmonary disease, restrictive lung disease, lung injury accompanied with autoimmune disease/connective tissue disorders.
• Have a history of severe cardiovascular disease.
• Have a history of significant hematologic toxicity to prior lines of therapy, as assessed by the investigator.
• Have uncontrolled hypertension or poorly controlled diabetes prior to allocation or randomization.
• Have concurrent malignancy within 5 years prior to allocation or randomization (protocol defined exceptions apply).
• Have unstable thrombotic event (e.g., deep vein thrombosis, arterial thrombosis, pulmonary embolism) requiring therapeutic intervention within 3 months prior to allocation or randomization, unless the participant has been fully treated (e.g., inferior vena cava filter placed) and/or adequately anticoagulated on a prophylactic dose.
• Have known human immunodeficiency virus infection or known acquired immunodeficiency syndrome (protocol defined exceptions apply).
• Have an active hepatitis B virus infection.
• Have an active hepatitis C virus (HCV) infection. Participants with a negative HCV antibody test at screening or positive HCV antibody test followed by a negative HCV ribonucleic acid test at screening are eligible. Participants who have completed curative antiviral treatment with HCV viral load below the limit of quantification are allowed.
• Have adverse reactions from prior anti-tumor therapy that have not returned to Grade ≤1, except for alopecia or toxicities (not specified elsewhere) considered irreversible and posing no safety risk to participants.
• Have active, or history of, autoimmune disease (e.g., myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, vasculitis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis) (protocol defined exceptions apply).
• Have serious non-healing wounds, ulcer, or bone fracture.
• Participants with lung cancer who have major coagulation disorders or an increased risk of hemorrhage (per investigator's clinical judgment)
• Have a history of serious Grade ≥3 immune-related adverse events (irAEs) that led to treatment discontinuation of a prior immunotherapy. Participants with a history of Grade ≥3 irAEs that did not lead to treatment discontinuation of a prior immunotherapy should be evaluated and determined by investigators for potential safety risk.
• Have a history of small bowel obstruction requiring hospitalization within the past 3 months prior to allocation or randomization.
• Current or prior use of immunosuppressive medication within 14 days before the first dose of study treatment (protocol defined exceptions apply).

• Have received any of the following therapies or drugs within the noted time intervals prior to allocation or randomization:

  • Systemic corticosteroids (at a dosage greater than 10 mg/day of prednisone or an equivalent dose of other corticosteroids) within 10 days prior to the initiation of study treatment.
  • Have been vaccinated with live, attenuated vaccine(s) within 4 weeks prior to initiation of the study treatment.

NOTE: Other protocol defined Inclusion/Exclusion criteria apply.